| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf2d37fb8041db82befb3065684c82b7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-644
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2014-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d56867a0f023433b56bc13ede1c45bef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a202e7b81451b3c54375d466d237f508
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c668332dc8cd022a70d38b97f69bc12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_16c4000256680bdda04c3373dd0e9c0d |
| publicationDate |
2014-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014129354-A |
| titleOfInvention |
Extended FIX analogs and derivatives |
| abstract |
Kind Code: A1 The present invention provides certain blood coagulation FIX analogs and derivatives that have an extended circulation time in the bloodstream compared to native factor IX (FIX). At least one of the natural amino acid residues at positions 146-180 is substituted with a cysteine amino acid residue to which a chemical group that increases the molecular weight of the FIX polypeptide is attached, and one or more amino acids at a specific position are substituted. It has a deleted or added amino acid sequence and has an extended circulatory half-life compared to that of native FIX (and one week after injection to the patient, compared to the initial peak activity value reached after injection). FIX polypeptide having biological activity for clot formation in vivo, retaining at least about 5% FIX activity). [Selection figure] None |
| priorityDate |
2006-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |